/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ceeable aims to be the next gold standard in visual fields

    A web-based, mobile digital technology designed to detect early-stage eye diseases—an innovation that can help shape 21st century medicine—was awarded third place in the American Medical Association’s inaugural Healthier Nation Innovation Challenge.

    Sponsored: Join us in San Francisco for dinner and DME discusson in August!

    The technology uses a cloud-based system, accessible on a tablet, to detect visual field changes and monitor the progression of eye diseases, such as age-related macular degeneration (AMD), glaucoma, and diabetic macular edema.The exam takes about 5 minutes per eye and involves patients using their index finger to trace grid patterns with various contrast levels. Rather than two-dimensional results, the digital exam allows physicians to see a volumetric change of the disease.

    Related: Gene-based treatment provides sustained AMD therapy

    The goal of the mobile digital technology is to increase patient access to the exam while decreasing the costs associated with it, said Chris Adams, chief executive officer of Ceeable.

    Dr. MatossianWhen patients undergo a traditional visual field, the patient is placed in a small, dark room for the exam that can take up to 15 minutes to complete per eye. Typical machinery for the exam has high costs and requires a dedicated room since it is “big, clunky, and not portable,” said Cynthia Matossian, MD, of Matossian Eye Associates, greater Philadelphia area, and medical advisor for Ceeable. The traditional visual field test also required a trained technician to be with the patient throughout the test.

    News: FDA approves one-of-a-kind IOL with extended range of vision

    The Ceeable technology, however, is mobile, meaning patients can be screened in any location where there is Internet service and do not need to have the exam in a pitch black “torture room” as Dr. Matossian referred to it.

    Adams is hopeful that the technology can replace the current gold standard, the Humphrey Field Analyzer (Carl Zeiss Meditech), since it can detect effected visual fields earlier while being a fraction of the cost. The technology can also track the progression of AMD before it converts to the “wet” form, as well as identify early-onset glaucoma.

    Timing issue

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results